Dr. Awan Discusses Challenges With Ibrutinib in CLL

Farrukh Awan, MBBS
Published: Monday, Oct 16, 2017



Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 
SELECTED
LANGUAGE


Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x